Toxicogenomics and classic toxicology: How to improve prediction and mechanistic understanding of human toxicity

Methods in Molecular Biology

Volumn 460, Issue , 2008, Pages 1-22

  Mendrick, Donna L ^a  

^a Gene Logic   (United States)

Author keywords

Hepatocytes; Hepatotoxicity; Idiosyncratic; Phenotypic anchoring; Toxicogenomics; Toxicology

Indexed keywords

EID: 84934437117     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-60327-48-9_1     Document Type: Article

References (49)

1. Kola, I. and Landis, J. (2004) Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711-715.
2. Mayne, J.T., Ku, W.W., and Kennedy, S.P. (2006) Informed toxicity assessment in drug discovery: systems-based toxicology. Curr. Opin. Drug Discov. Dev. 9, 75-83.
3. Barros, S.A. (2005) The importance of applying toxicogenomics to increase the efficiency of drug discovery. Pharmacogenomics 6, 547-550.
4. DiMasi, J.A., Hansen, R.W., and Grabowski, H.G. (2003) The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151-185.
5. Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., et al. (2000) Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 32, 56-67.
6. Suter, L., Babiss, L.E., and Wheeldon, E.B. (2004) Toxicogenomics in predictive toxicology in drug development. Chem. Biol. 11, 161-171.
7. DiMasi, J.A. (2002) The value of improving the productivity of the drug development process: faster times and better decisions. Pharmacoeconomics 20 (Suppl 3), 1-10.
8. Boverhof, D.R. and Zacharewski, T.R. (2006) Toxicogenomics in risk assessment: applications and needs. Toxicol. Sci. 89, 352-360.
9. Yang, Y., Blomme, E.A., and Waring, J.F. (2004) Toxicogenomics in drug discovery: from preclinical studies to clinical trials. Chem. Biol. Interact. 150, 71-85.
10. Luhe, A., Suter, L., Ruepp, S., Singer, T., Weiser, T., and Albertini, S. (2005) Toxicogenomics in the pharmaceutical industry: hollow promises or real benefit? Mutat. Res. 575, 102-115.
11. Lord, P.G. (2004) Progress in applying genomics in drug development. Toxicol. Lett. 149, 371-375.
12. Searfoss, G.H., Ryan, T.P., and Jolly, R.A. (2005) The role of transcriptome analysis in pre-clinical toxicology. Curr. Mol. Med. 5, 53-64.
13. Guerreiro, N., Staedtler, F., Grenet, O., Kehren, J., and Chibout, S.D. (2003) Toxicogenomics in drug development. Toxicol. Pathol. 31, 471-479.
14. Dix, D.J., Houck, K.A., Martin, M.T., Richard, A.M., Setzer, R.W., and Kavlock, R.J. (2007) The ToxCast Program for Prioritizing Toxicity Testing of Environmental Chemicals. Toxicol. Sci. 95, 5-12.
15. Lord, P.G., Nie, A., and McMillian, M. (2006) Application of genomics in preclinical drug safety evaluation. Basic Clin. Pharmacol. Toxicol. 98, 537-546.
16. Shioda, T., Chesnes, J., Coser, K.R., Zou, L., Hur, J., Dean, K.L., et al. (2006) Importance of dosage standardization for interpreting transcriptomal signature profiles: evidence from studies of xenoestrogens. Proc. Natl. Acad. Sci. U. S. A. 103, 12033-12038.
17. Farr, S. and Dunn, R.T. II (1999) Concise review: gene expression applied to toxicology. Toxicol. Sci. 50, 1-9.
18. Heinloth, A.N., Irwin, R.D., Boorman, G.A., Nettesheim, P., Fannin, R.D., Sieber, S.O., et al. (2004) Gene expression profiling of rat livers reveals indicators of potential adverse effects. Toxicol. Sci. 80, 193-202.
19. Nie, A.Y., McMillian, M., Brandon, P.J., Leone, A., Bryant, S., Yieh, L., et al. (2006) Predictive toxicogenomics approaches reveal underlying molecular mechanisms of nongenotoxic carcinogenicity. Mol. Carcinog. 45, 914-933.
20. Mattes, W.B., Daniels, K.K., Summan, M., Xu, Z.A., and Mendrick, D.L. (2006) Tissue and species distribution of the glutathione pathway transcriptome. Xenobiotica 36, 1081-1121.
21. Martin, R., Rose, D., Yu, K., and Barros, S. (2006) Toxicogenomics strategies for predicting drug toxicity. Pharmacogenomics 7, 1003-1016.
22. Hultin-Rosenberg, L., Jagannathan, S., Nilsson, K.C., Matis, S.A., Sjogren, N., Huby, R.D., et al. (2006) Predictive models of hepatotoxicity using gene expression data from primary rat hepatocytes. Xenobiotica 36, 1122-1139.
23. Kaplowitz, N. (2005) Idiosyncratic drug hepatotoxicity. Nat. Rev. Drug Discov. 4, 489-499.
24. Dieckhaus, C.M., Miller, T.A., Sofia, R.D., and Macdonald, T.L. (2000) A mechanistic approach to understanding species differences in felbamate bioactivation: relevance to drug-induced idiosyncratic reactions. Drug Metab. Dispos. 28, 814-822.
25. Alden, C., Lin, J., and Smith, P. (2003) Predicting toxicology technology for avoiding idiosyncratic liver injury. Preclinica May/June, 27-35.
26. Popovic, M., Nierkens, S., Pieters, R., and Uetrecht, J. (2004) Investigating the role of 2-phenylpropenal in felbamate-induced idiosyncratic drug reactions. Chem. Res. Toxicol. 17, 1568-1576.
27. Ettinger, A.B., Jandorf, L., Berdia, A., Andriola, M.R., Krupp, L.B., and Weisbrot, D.M. (1996) Felbamate-induced headache. Epilepsia 37, 503-505.
28. McGee, J.H., Erikson, D.J., Galbreath, C., Willigan, D.A., and Sofia, R.D. (1998) Acute, subchronic, and chronic toxicity studies with felbamate, 2-phenyl-1.,3-propanediol dicarbamate. Toxicol. Sci. 45, 225-232.
29. Carvajal Garcia-Pando, A., Garcia, d.P., Sanchez, A.S., Velasco, M.A., Rueda de Castro, A.M., and Lucena, M.I. (2002) Hepatotoxicity associated with the new antidepressants. J. Clin. Psychiatry 63, 135-137.
30. Stewart, D.E. (2002) Hepatic adverse reactions associated with nefazodone. Can. J. Psychiatry 47, 375-377.
31. Choi, S. (2003) Nefazodone (Serzone) withdrawn because of hepatotoxicity. CMAJ. 169, 1187.
32. Aranda-Michel, J., Koehler, A., Bejarano, P.A., Poulos, J.E., Luxon, B.A., Khan, C.M., et al. (1999) Nefazodone-induced liver failure: report of three cases. Ann. Intern. Med. 130, 285-288.
33. Schrader, G.D. and Roberts-Thompson, I.C. (1999) Adverse effect of nefazodone: hepatitis. Med. J. Aust. 170, 452.
34. Kostrubsky, S.E., Strom, S.C., Kalgutkar, A.S., Kulkarni, S., Atherton, J., Mireles, R., et al. (2006) Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone. Toxicol. Sci. 90, 451-459.
35. Greene, D.S. and Barbhaiya, R.H. (1997) Clinical pharmacokinetics of nefazodone. Clin. Pharmacokinet. 33, 260-275.
36. DeVane, C.L., Donovan, J.L., Liston, H.L., Markowitz, J.S., Cheng, K.T., Risch, S.C., and Willard, L. (2004) Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers. J. Clin. Psychopharmacol. 24, 4-10.
37. Kalgutkar, A.S., Vaz, A.D., Lame, M.E., Henne, K.R., Soglia, J., Zhao, S.X., et al. (2005) Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P450 3A4. Drug Metab. Dispos. 33, 243-253.
38. Kostrubsky, V.E., Strom, S.C., Hanson, J., Urda, E., Rose, K., Burliegh, J., et al. (2003) Evaluation of hepatotoxic potential of drugs by inhibition of bile-acid transport in cultured primary human hepatocytes and intact rats. Toxicol. Sci. 76, 220-228.
39. Landis, G.N. and Tower, J. (2005) Superoxide dismutase evolution and life span regulation. Mech. Ageing Dev. 126, 365-379.
40. Dambach, D.M., Andrews, B.A., and Moulin, F. (2005) New technologies and screening strategies for hepatotoxicity: use of in vitro models. Toxicol. Pathol. 33, 17-26.
41. Meador, V., Jordan, W., and Zimmermann, J. (2002) Increasing throughput in lead optimization in vivo toxicity screens. Curr. Opin. Drug Discov. Dev. 5, 72-78.
42. Liguori, M.J., Anderson, L.M., Bukofzer, S., McKim, J., Pregenzer, J.F., Retief, J., et al. (2005) Microarray analysis in human hepatocytes suggests a mechanism for hepatotoxicity induced by trovafloxacin. Hepatology 41, 177-186.
43. Waring, J.F., Ciurlionis, R., Jolly, R.A., Heindel, M., and Ulrich, R.G. (2001) Microarray analysis of hepatotoxins in vitro reveals a correlation between gene expression profiles and mechanisms of toxicity. Toxicol. Lett. 120, 359-368.
44. Sawada, H., Takami, K., and Asahi, S. (2005) A toxicogenomic approach to druginduced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol. Sci. 83, 282-292.
45. Reynolds, V.L. (2005) Applications of emerging technologies in toxicology and safety assessment. Int. J. Toxicol. 24, 135-137.
46. Shi, L., Reid, L.H., Jones, W.D., Shippy, R., Warrington, J.A., Baker, S.C., et al. (2006) The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat. Biotechnol. 24, 1151-1161.
47. Canales, R.D., Luo, Y., Willey, J.C., Austermiller, B., Barbacioru, C.C., Boysen, C., et al. (2006) Evaluation of DNA microarray results with quantitative gene expression platforms. Nat. Biotechnol. 24, 1115-1122.
48. Guo, L., Lobenhofer, E.K., Wang, C., Shippy, R., Harris, S.C., Zhang, L., et al. (2006) Rat toxicogenomic study reveals analytical consistency across microarray platforms. Nat. Biotechnol. 24, 1162-1169.
49. Goodsaid, F. and Frueh, F. (2006) Process map proposal for the validation of genomic biomarkers. Pharmacogenomics 7, 773-782.